We thank Samson et al for their interest in our article on ustekinumab in giant-cell arteritis (GCA) and for their comments on our study.1 2 Our initial pilot study reported promising results with the use of ustekinumab in refractory GCA.1 GCA is associated with considerable disease-related and treatment-related morbidity.3 4 While glucocorticoids remain the cornerstone of treatment, the associated increased rates of adverse events such as fractures, sepsis, hypertension and diabetes mellitus are significant concerns to both physicians and patients.4 There is a critical unmet need for new treatment options in GCA to minimise the cumulative glucocorticoid burden …

中文翻译：

---

响应：乌司奴单抗抑制巨细胞动脉炎患者的 Th1 和 Th17 极化 Samson 等人

我们感谢 Samson 等人对我们关于优特克单抗治疗巨细胞动脉炎 (GCA) 的文章的兴趣以及他们对我们研究的评论。1 2 我们的初步试点研究报告了使用优特克单抗治疗难治性 GCA 的有希望的结果。1 GCA 是3 4 虽然糖皮质激素仍然是治疗的基石，但相关的不良事件（如骨折、败血症、高血压和糖尿病）发生率增加是医生和患者都非常关注的问题。4是 GCA 新治疗方案的关键未满足需求，以最大限度地减少累积糖皮质激素负担……